Literature DB >> 23594015

Treatment target in polycythemia vera.

Josef T Prchal, Victor R Gordeuk.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23594015     DOI： 10.1056/NEJMc1301262

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials.

Authors:  John Mascarenhas; Ruben Mesa; Josef Prchal; Ronald Hoffman
Journal:  Haematologica       Date:  2014-06       Impact factor: 9.941

2.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Authors:  Alessandro M Vannucchi; Jean Jacques Kiladjian; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Ruben Mesa; Shui He; Mark M Jones; William Garrett; Jingjin Li; Ulrich Pirron; Dany Habr; Srdan Verstovsek
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

Review 3.  Red blood cells in thrombosis.

Authors:  James R Byrnes; Alisa S Wolberg
Journal:  Blood       Date:  2017-08-15       Impact factor: 22.113

Review 4.  Experience with ruxolitinib in the treatment of polycythaemia vera.

Authors:  Samah Alimam; Claire Harrison
Journal:  Ther Adv Hematol       Date:  2017-04-01

Review 5.  Hematocrit, White Blood Cells, and Thrombotic Events in the Veteran Population With Polycythemia Vera.

Authors:  Tsewang Tashi
Journal:  Fed Pract       Date:  2022-03-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.